Doxofylline: Advancing and Empowering Equitable Asthma and COPD Management Beyond Tradition

Author:

Cazzola Mario1ORCID,Page Clive P.2,Calzetta Luigino3,Rogliani Paola1,Matera Maria Gabriella4

Affiliation:

1. Unit of Respiratory Medicine Department of Experimental Medicine University of Rome “Tor Vergata” Rome 00133 Italy

2. Sackler Institute of Pulmonary Pharmacology Institute of Pharmaceutical Science King's College London London SE1 9NH UK

3. Department of Medicine and Surgery Respiratory Disease and Lung Function Unit University of Parma Parma 43126 Italy

4. Unit of Pharmacology Department of Experimental Medicine University of Campania “Luigi Vanvitelli” Naples 80138 Italy

Abstract

AbstractDoxofylline, a newer methylxanthine derivative, has garnered increasing attention for its distinct pharmacological properties and therapeutic advantages over traditional agents such as theophylline. This paper provides a comprehensive review of the pharmacological characteristics and clinical efficacy of doxofylline, elucidating why it represents a significant advancement in methylxanthine therapy. Moreover, attention is given to the economic considerations surrounding its utilization, particularly in low‐ and medium‐income countries where access to healthcare resources is limited. The affordability, improved tolerability, and dosing convenience of doxofylline make it a promising candidate for addressing the substantial burden of asthma and COPD in resource‐constrained settings.

Publisher

Wiley

Reference84 articles.

1. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019

2. Access to cardiovascular medicines in low- and middle-income countries: a mini review

3. World Health Organization Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020.https://apps.who.int/iris/bitstream/handle/10665/94384/9789241506236_eng.pdf?sequence=1a (accessed: January 2024).

4. Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries

5. World Health Organization WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care https://www.who.int/publications/i/item/9789240009226(accessed: May 2024).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3